Emerging treatments for pulmonary arterial hypertension.
O'Callaghan
Dermot S
DS
Department of Respiratory Medicine, Master Misericordiae University Hospital, University College Dublin, Dublin, Ireland. dsocallaghan@yahoo.com
D000959:Antihypertensive Agents / Q000627:therapeutic use; D002908:Chronic Disease; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology*; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors; D011379:Prognosis; D011453:Prostaglandins / Q000627:therapeutic use*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome; D014660:Vasoactive Intestinal Peptide / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D058986:Phosphodiesterase 5 Inhibitors; D011453:Prostaglandins; D014660:Vasoactive Intestinal Peptide; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5